Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7121392 | 0.88 | KDM4E (0.65) | GSK3BKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7124017 | 0.84 | KDM4E (0.46) | GSK3BKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7114815 | 0.82 | ALDH1A1 (0.67) | KDM5AGSK3BKDM4EALDH1A1HPGD | |
| SCHEMBL7123791 | 0.80 | KEAP1 (0.54) | GSK3BKDM4EALDH1A1KEAP1NFE2L2 | |
| SCHEMBL10050059 | 0.78 | KDM4E (0.77) | KDM5AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7114063 | 0.77 | GSK3B (0.47) | GSK3BKDM4EALDH1A1KEAP1NFE2L2 | |
| SCHEMBL6519610 | 0.76 | GSK3B (0.56) | GSK3BKDM4EALDH1A1KEAP1NFE2L2 | |
| SCHEMBL7114921 | 0.76 | DAO (0.46) | GSK3BKDM4EALDH1A1KEAP1NFE2L2 | |
| SCHEMBL3422670 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1HPGDKEAP1NFE2L2 | |
| SCHEMBL1060499 | 0.75 | KDM5A (0.59) | KDM5AGSK3BKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| EP-1244629-A2 | QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001046150-A2 | QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | IRF3, MAVS, NQO2 | KDM5A 2603/4885GSK3B 1499/4885KDM4E 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.